Neurobiology of Aging
Volume 30, Issue 11 , Pages 1805-1817 , November 2009

Microglial responses to dopamine in a cell culture model of Parkinson's disease

  • Diego Mastroeni

      Affiliations

    • Sun Health Research Institute, 10515 West Santa Fe Drive, Sun City, AZ 85372, United States
    • ,
  • Andrew Grover

      Affiliations

    • Sun Health Research Institute, 10515 West Santa Fe Drive, Sun City, AZ 85372, United States
    • ,
  • Brian Leonard

      Affiliations

    • Sun Health Research Institute, 10515 West Santa Fe Drive, Sun City, AZ 85372, United States
    • ,
  • Jeffrey N. Joyce

      Affiliations

    • Sun Health Research Institute, 10515 West Santa Fe Drive, Sun City, AZ 85372, United States
    • ,
  • Paul D. Coleman

      Affiliations

    • Sun Health Research Institute, 10515 West Santa Fe Drive, Sun City, AZ 85372, United States
    • ,
  • Brooke Kozik

      Affiliations

    • Department of Pathology and Human Anatomy, Loma Linda University School of Medicine, Loma Linda, CA 92350, United States
    • ,
  • Denise L. Bellinger

      Affiliations

    • Department of Pathology and Human Anatomy, Loma Linda University School of Medicine, Loma Linda, CA 92350, United States
    • ,
  • Joseph Rogers

      Affiliations

    • Sun Health Research Institute, 10515 West Santa Fe Drive, Sun City, AZ 85372, United States
    • Corresponding Author InformationCorresponding author at: Sun Health Research Institute, P.O. Box 1278, Sun City, AZ 85372, United States. Tel.: +1 623 876 5466; fax: +1 623 876 5461.

Received 1 October 2007 ,Revised 9 January 2008 ,Accepted 13 January 2008.

References 

  1. Akiyama H, McGeer PL. Microglial response to 6-hydroxydopamine-induced substantia nigra lesions. Brain Res. 1989;489:247–253
  2. Akiyama H, McGeer PL. Brain microglia constitutively express beta-2 integrins. J. Neuroimmunol. 1990;30:81–93
  3. Arimoto T, Bing G. Up-regulation of inducible nitric oxide synthase in the substantia nigra by lipopolysaccharide causes microglial activation and neurodegeneration. Neurobiol. Dis. 2003;12:35–45
  4. Chang RC, Hudson PM, Wilson BC, Liu B, Abel H, Hong JS. High concentrations of extracellular potassium enhance bacterial endotoxin lipopolysaccharide-induced neurotoxicity in glia-neuron mixed cultures. Neuroscience. 2000;97:757–764
  5. Chen H, Zhang SM, Hernan MA, Schwarzschild MA, Willet WC, Colditz GA, et al. Nonsteroidal anti-inflammatory drugs and the risk of Parkinson disease. Arch. Neurol. 2003;60:1059–1064
  6. Chen H, Jacobs E, Schwarzschild MA, McCullough ML, Calle EE, Thun MJ, et al. Nonsteroidal anti-inflammatory drug use and the risk for Parkinson disease. Ann. Neurol. 2005;58:963–967
  7. De la Torre JC, Surgeon JW. Histochemical fluorescence of tissue and brain monoamines, results in 18min using sucrose-phosphate-glyoxylic acid (SPG) method. Neuroscience. 1976;1:451–453
  8. Denker SP, Ji S, Dingman A, Lee SY, Derugin N, Wendland MF, et al. Macrophages are comprised of resident brain microglia not infiltrating peripheral monocytes acutely after neonatal stroke. J. Neurochem. 2007;100:893–904
  9. Encinas M, Iglesias M, Liu Y, Hongyin W, Muhaisen A, Cena V, et al. Sequential treatment of SH-SY5Y cells with retinoic acid and brain-derived neurotrophic factor gives rise to fully differentiated, neurotrophic factor-dependent, human neuron-like cells. J. Neurochem. 2000;75:991–1003
  10. Falkenburger BH, Schulz JB. Limitations of cellular models in Parkinson's disease research. J. Neural Transm. 2006;70:261–268
  11. Farber K, Pannasch U, Kettenmann H. Dopamine and noradrenaline control distinct functions in rodent microglial cells. Mol. Cell Neurosci. 2005;29:128–138
  12. Gao HM, Jiang J, Wilson B, Zhang W, Hong JS, Liu B. Microglial activation-mediated delayed and progressive degeneration of rat nigral dopaminergic neurons, relevance to Parkinson's disease. J. Neurochem. 2002;81:1285–1297
  13. Gao HM, Liu B, Zhang W, Hong JS. Novel anti-inflammatory therapy for Parkinson's disease. Trends Pharmacol. Sci. 2003;24:395–401
  14. Grima G, Benz B, Parpura V, Cuenod M, Do KQ. Dopamine-induced oxidative stress in neurons with glutathione deficit, implication for schizophrenia. Schizophr. Res. 2003;62:213–224
  15. Gross J, Ungethum U, Andreeva N, Heldt J, Gao J, Marschhausen G, et al. Hypoxia during early developmental period induces long-term changes in the dopamine content and release in a mesencephalic cell culture. Neuroscience. 1999;92:699–704
  16. Hayashi M, Luo Y, Laning J, Strieter RM, Dorf ME. Production and function of monocyte chemoattractant protein-1 and other beta-chemokines in murine glial cells. J. Neuroimmunol. 1995;60:143–150
  17. Hernan MA, Logroscino G, Garcia-Rodriguez LA. Nonsteroidal anti-inflammatory drugs and the incidence of Parkinson disease. Neurology. 2006;66:1097–1099
  18. Herrera AJ, Tomas-Camardiel M, Venero JL, Cano J, Machado A. Inflammatory process as a determinant factor for the degeneration of substantia nigra dopaminergic neurons. J. Neural Transm. 2005;112:111–119
  19. Hunter RL, Dragicevic N, Seifert K, Choi DY, Liu M, Kim HC, et al. Inflammation induces mitochondrial dysfunction and dopaminergic neurodegeneration in the nigrostriatal system. J. Neurochem. 2007;100:1375–1386
  20. Irvani MM, Leung CC, Sadeghian M, Haddon CO, Rose S, Jenner P. The acute and the long-term effects of nigral lipopolysaccharide administration on dopaminergic dysfunction and glial cell activation. Eur. J. Neurosci. 2005;22:317–330
  21. Jack C, Ruffini F, Bar-Or A, Antel JP. Microglia and multiple sclerosis. J. Neurosci. Res. 2005;81:363–373
  22. Kim SU. Antigen expression by glial cells grown in culture. J. Neuroimmunol. 1985;8:255–282
  23. Kim YS, Joh TH. Microglia, major player in the brain inflammation, their roles in the pathogenesis of Parkinson's disease. Exp. Mol. Med. 2006;38:333–347
  24. Kim SU, de Vellis J. Microglia in health and disease. J. Neurosci. Res. 2005;81:302–313
  25. Kim W-G, Mohney RP, Wilson B, Jeohn G-H, Liu B, Hong J-S. Regional difference in susceptibility to lipopolysaccharide-induced neurotoxicity in the rat brain, role of microglia. Neuroscience. 2000;20:6309–6316
  26. Kokovay E, Cunningham LA. Bone marrow-derived microglia contribute to the neuroinflammatory response and express iNOS in the MPTP mouse model of Parkinson's disease. Neurobiol. Dis. 2005;19:471–478
  27. Kostrzewa RM, Kostrzewa JP, Brus R. Neuroprotective and neurotoxic roles of levodopa (l-DOPA) in neurodegenerative disorders relating to Parkinson's disease. Amino Acids. 2002;23:57–63
  28. Lawson LJ, Perry VH, Dri P, Gordon S. Heterogeneity in the distribution and morphology of microglia in the normal adult mouse brain. Neuroscience. 1990;39:151–170
  29. Lue LF, Brachova L, Walker DG, Rogers J. Characterization of glial cultures from rapid autopsies of Alzheimer's and control patients. Neurobiol. Aging. 1996;17:421–429
  30. Lue LF, Walker DG, Rogers J. Modeling microglial activation in Alzheimer's disease with human postmortem microglial cultures. Neurobiol. Aging. 2001;22:945–956
  31. Lui B. Modulation of microglial pro-inflammatory and neurotoxic activity for the treatment of Parkinson's disease. AAPS J. 2006;8:606–621
  32. Maat-Schieman ML, Rozemuller AJ, van Duinen SG, Haan J, Eikelenboom P, Roos RA. Microglia in diffuse plaques in hereditary cerebral hemorrhage with amyloidosis (Dutch) an immunohistochemical study. J. Neuropathol. Exp. Neurol. 1994;53:483–491
  33. Marra F, Romanelli RG, Giannini C, Failli P, Pastacaldi S, Arrighi MC, et al. Monocyte chemotactic protein-1 as a chemoattractant for human hepatic stellate cells. Heptology. 1999;29:140–148
  34. McGeer PL, Itagaki S, Boyes BE, McGeer EG. Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains. Neurology. 1988;38:1285–1291
  35. McGeer PL, Rogers J, McGeer EG. Inflammation, anti-inflammatory agents and Alzheimer disease, the last 12 years. Alzheimer's Dis. 2006;9:271–276
  36. Minagar A, Shapshak P, Fujimura R, Ownby R, Heyes M, Eisdorfer C. The role of macrophage/microglia and astrocytes in the pathogenesis of three neurologic disorders, HIV-associated dementia, Alzheimer disease, and multiple sclerosis. J. Neurol. Sci. 2002;202:12–23
  37. Nelson PT, Soma LA, Lavi E. Microglia in diseases of the central nervous system. Ann. Med. 2002;34:491–500
  38. Nicoll JA, Barton E, Boche D, Neal JW, Ferrer I, Thompson P, et al. A beta species removal after a beta 42 immunization. Neuropathol. Exp. Neurol. 2006;65:1040–1048
  39. Nutile-McMenemy N, Elfenbein A, Deleo JA. Minocycline decreases in vitro microglial motility, beta1-integrin, and Kv13 channel expression. J. Neurochem. 2007;103:2035–2046
  40. Pahlman S, Hoehner JC, Nanberg E, Hedborg F, Fagerstrom S, Gestblom C, et al. Differentiation and survival influences of growth factors in human neuroblastoma. Eur. J. Cancer. 1995;31:453–458
  41. Peng GS, Li G, Tzeng NS, Chen PS, Chuang DM, Hsu YD, et al. Valproate pretreatment protects dopaminergic neurons from LPS-induced neurotoxicity in rat primary midbrain cultures, role of microglia. Brain Res. Mol. Brain Res. 2005;134:162–169
  42. Perlmutter LS, Scott SA, Barron E, Chui HC. MCH class II-positive microglia in human brain, association with Alzheimer lesions. J. Neurosci. Res. 1992;33:549–558
  43. Platten M, Kretz A, Naumann U, Aulwurm S, Egashira K, Isenmann S, et al. Monocyte chemoattractant protein-1 increases microglial infiltration and aggressiveness of gliomas. Ann. Neurol. 2003;54:388–392
  44. Presgraves SP, Ahmed T, Borwege S, Joyce JN. Terminally differentiated SH-SY5Y cells provide a model system for studying neuroprotective effects of dopamine agonists. Neurotoxicol. Res. 2004;5:579–598
  45. Rice PA, Boehm GW, Moynihan JA, Bellinger DL, Stevens SY. Chemical sympathectomy alters numbers of splenic and peritoneal leukocytes. Brain Behav. Immunol. 2002;16:62–73
  46. Rogers J, Strohmeyer R, Kovelowski CJ, Li R. Microglia and inflammatory mechanisms in the clearance of amyloid beta peptide. Glia. 2002;40:260–269
  47. Roy B, Rai U. Dual mode of catecholamine action on splenic macrophage phagocytosis in wall lizard, Hemidactylus flaviviridis. Gen. Comp. Endocrinol. 2004;136:180–191
  48. Seeman P, Van Tol HH. Dopamine receptor pharmacology. Trends Pharmacol. Sci. 1994;15:264–270
  49. Shalaby IA, Kotake C, Hoffman PC, Heller A. Release of dopamine from coaggregate cultures of mesencephalic tegmentum and corpus striatum. J. Neurosci. 1983;3:1565–1571
  50. Su, X., Maguire-Zeiss, K.A., Giuliano, R., Prifti, L., Venkatesh, K., Federoff, H.J., 2007. Synuclein activates microglia in a model of Parkinson's disease. Neurobiol. Aging, doi:10.1016/j.neurobiolaging.2007.04.006, in press.
  51. Teismann P, Schulz JB. Cellular pathology of Parkinson's disease, astrocytes, microglia and inflammation. Cell Tissue Res. 2004;318:149–161
  52. Thompson MD, Burnham WM, Cole DE. The G protein-coupled receptors: pharmacogenetics and disease. Crit. Rev. Clin. Lab. Sci. 2005;42:311–392
  53. Walker DG, Lue LF. Investigations with cultured human microglia on pathogenic mechanisms of Alzheimer's disease and other neurodegenerative diseases. J. Neurosci. Res. 2005;81:412–425
  54. Wang T, Rumbaugh JA, Nath A. Viruses and the brain: from inflammation to dementia. Clin. Sci. 2006;110:393–407
  55. Xue M, Del Bigio MR. Comparison of brain cell death and inflammatory reaction in three models of intracerebral hemorrhage in adult rats. J. Stroke Cerebrovasc. Dis. 2003;12:152–159
  56. Zhou HF, Liu XY, Niu DB, Li FQ, He QH, Wang XM. Triptolide protects dopaminergic neurons from inflammation-mediated damage induced by lipopolysaccharide intranigral injection. Neurobiol. Dis. 2005;18:441–449

PII: S0197-4580(08)00011-0

doi: 10.1016/j.neurobiolaging.2008.01.001

Neurobiology of Aging
Volume 30, Issue 11 , Pages 1805-1817 , November 2009

Article Tools

* Image Usage & Resolution